Reuters logo
BRIEF-Merck withdraws European application for Keytruda
October 27, 2017 / 8:34 PM / 23 days ago

BRIEF-Merck withdraws European application for Keytruda

Oct 27 (Reuters) - Merck & Co Inc:

* Merck provides update on European application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for first-line treatment of nonsquamous non-small cell lung cancer (NSCLC)

* Withdrawn European application for Keytruda in combination with pemetrexed, carboplatin as first-line treatment for metastatic nonsquamous NSCLC

* Company is confident in clinical data from Keynote-021, Cohort G​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below